

Curriculum Vitae

Personal information Christian B. (Kit) Roes

Work experience

1. Employer: Radboud University Medical Centre
 - Start date: 082019
 - End date:
 - Position: Professor of Biostatistics
 - Activities:
 - Country: Netherlands
2. Employer: CBG_MEB
 - Start date: 032010
 - End date:
 - Position: Senior assessor Methodology & former chair Working Group Methodology
 - Activities:
 - Country: Netherlands
3. Employer: UMC Utrecht
 - Start date: 092016
 - End date: 082019
 - Position: Professor of Clinical Trial Methodology
 - Activities:
 - Country: Netherlands
4. Employer: UMC Utrecht
 - Start date: 042013
 - End date: 092016
 - Position: Director Quality and Patient Safety
 - Activities:
 - Country: Netherlands
5. Employer: UMC Utrecht
 - Start date: 092009
 - End date: 092016
 - Position: Professor of Biostatistics
 - Activities:
 - Country: Netherlands
6. Employer: Schering_Plough / Formerly Organon
 - Start date: 042002
 - End date: 082009
 - Position: Vice President Global Clinical Information
 - Activities: Global Head of Biostatistics, Data Management, Medical Writing and Contract Management. Includes previous positions as local Head Clinical Information, Director Biometrics.
 - Country: Netherlands
7. Employer: Wageningen University and Research Center
 - Start date: 041997
 - End date: 032002
 - Position: Business Unit Manager Biometry
 - Activities:
 - Country: Netherlands
8. Employer: University of Amsterdam
 - Start date: 021995
 - End date: 031997
 - Position: Senior consultant / Researcher
 - Activities:
 - Country: Netherlands
9. Employer: Organon
 - Start date: 071991
 - End date: 011995
 - Position: Senior statistician
 - Activities:
 - Country: Netherlands
10. Employer: Philips Electronics
 - Start date: 111985
 - End date: 061995
 - Position: Consultant Statistics / Head Industrial Statistics
 - Activities:
 - Country: Netherlands

Education and training

1. Subject: Harvard Business School
 - Start date: 122015
 - End date: 122015
 - Qualification: None
 - Organisation: Value Measurement in Healthcare
 - Country: United States
2. Subject: Nyenrode University

- Start date: 012002
 - End date: 122002
 - Qualification: Certificate
 - Organisation: Advanced Management Program
 - Country: Netherlands
3. Subject: University of Amsterdam
- Start date: 091990
 - End date: 111995
 - Qualification: PhD
 - Organisation: Mathematics/Statistics
 - Country: Netherlands
4. Subject: University Nijmegen
- Start date: 081980
 - End date: 111985
 - Qualification: Msc
 - Organisation: Mathematics
 - Country: Netherlands

Additional information

Publications

1. van Karnebeek CDM, Müller AR, Benkemoun L, Boussaad I, Cornel MC, Inthout J, de Kort M, de Oliveira Martins S, Prigione A, Rigter T, Roes KCB, Sanchez A, Schipper R, Wilkinson MD, 't Hoen PAC. SIMPATHIC: Accelerating drug repurposing for rare diseases by exploiting SIMilarities in clinical and molecular PATHology. *Mol Genet Metab*. 2025 Apr;144(4):109073. doi: 10.1016/j.ymgme.2025.109073. Epub 2025 Mar 1.
2. Storosum BWC, Cohen SE, Steinz CA, Mattila TK, Welten CC, van den Brink W, Roes K, de Haan L, Denys DAJP, Zantvoord JB. Ethnic differences in efficacy of drug treatment in patients with an acute manic episode: an individual patient data meta-analysis of randomized placebo-controlled trials. *Int J Bipolar Disord*. 2025 Feb 23;13(1):8. doi: 10.1186/s40345-025-00371-0.
3. Jiang C, Beji C, Zebachi S, Hayek GY, Cetinyurek-Yavuz A, Fayyad MBN, Rodwell L, Roes KCB, Amzal B, Gerlinger C, Porcher R, Tanniou J. Decision-Making Criteria and Methods for Initiating Late-Stage Clinical Trials in Drug Development From a Multi-Stakeholder Perspective: A Scoping Review. *Clin Pharmacol Ther*. 2025 Apr;117(4):978-988. doi: 10.1002/cpt.3566.
4. Arlett P, Umuhire D, Verpillat P, Foggi P, Wändel Liminga U, Sepodes B, Lunzer M, Aylward B, Vamvakas S, Roes K, Pétavy F, Thirstrup S, Lamas M, Cooke E, Broich K. Clinical Evidence 2030. *Clin Pharmacol Ther*. 2025 Apr;117(4):884-886. doi: 10.1002/cpt.3596.
5. Daletzikis A, Roes KCB, Jonker MA. Estimation of the Restricted Mean Duration of Response (RMDoR) in Oncology. *Pharm Stat*. 2025 Jan-Feb;24(1):e2468. doi: 10.1002/pst.2468.
6. Cetinyurek Yavuz A, Fayyad MBN, Jiang C, Brion Bouvier F, Beji C, Zebachi S, Hayek GY, Amzal B, Porcher R, Tanniou J, Roes K, Rodwell L. On the Concepts, Methods, and Use of "Probability of Success" for Drug Development Decision-Making: A Scoping Review. *Clin Pharmacol Ther*. 2025 Apr;117(4):967-977. doi: 10.1002/cpt.3571.
7. van Boven JFM, Costello RW, Roes KCB, Brusselle GG, Hansen K, Krishnan JA, Brightling CE, Roche N, Siddiqui S, Kirenga BJ, Pinnock H, Chan AHY. Augmenting clinical trials in asthma through digital technology, decentralised designs, and person-centric endpoints: opportunities and challenges. *Lancet Respir Med*. 2025 Feb;13(2):177-188. doi: 10.1016/S2213-2600(24)00327-8.
8. Storosum BWC, Cohen SE, Mattila TK, Roes KCB, Welten C, van den Brink W, de Haan L, Denys D, Zantvoord JB. Gender differences in the response to antipsychotics or mood stabilizers in patients with acute mania: An individual patient data meta-analysis of placebo-controlled studies. *J Psychiatr Res*. 2025 Jan;181:358-364. doi: 10.1016/j.jpsychires.2024.11.014.
9. Correia Pinheiro L, Arlett P, Roes K, Musuamba Tshinanu F, Westman G, Frias Z, Hamann H, Berenguer Jornet J, Khan I, Larsen J, Broich K, Cooke E. Artificial Intelligence in European Medicines Regulation: From Vision to Action. Harnessing the Capabilities of Artificial Intelligence for the Benefit of Public and Animal Health. *Clin Pharmacol Ther*. 2025 Feb;117(2):335-336. doi: 10.1002/cpt.3494.
10. Chesshyre ELD, Bradbury JD, Cook H, Rocchi F, Roes K, Turner MA, Brüggemann R, Warris A. The impact of the COVID-19 pandemic and the changing landscape of CF on the cASPerCF trial: a real-world experience. *Trials*. 2024 Oct 2;25(1):645. doi: 10.1186/s13063-024-08510-1.
11. Cartwright MJ, Friede T, Lawrence D, May E, Mütze T, Roes K. Stakeholders' Perspectives on Current Issues in Data Monitoring Committees. *Biom J*. 2024 Oct;66(7):e202300384. doi: 10.1002/bimj.202300384.
12. Malizia V, de Vlas SJ, Roes KCB, Giardina F. Revisiting the impact of *Schistosoma mansoni* regulating mechanisms on transmission dynamics using SchiSTOP, a novel modelling framework. *PLoS Negl Trop Dis*. 2024 Sep 20;18(9):e0012464. doi: 10.1371/journal.pntd.0012464.
13. Chu WY, Nijman M, Stegeman R, Breur JMPJ, Jansen NJG, Nijman J, van Loon K, Koomen E, Allegaert K, Benders MJNL, Dorlo TPC, Huitema ADR; CRUCIAL trial consortium. Population Pharmacokinetics and Target Attainment of Allopurinol and Oxypurinol Before, During, and After Cardiac Surgery with Cardiopulmonary Bypass in Neonates with Critical Congenital Heart Disease. *Clin Pharmacokinet*. 2024 Aug;63(8):1205-1220. doi: 10.1007/s40262-024-01401-3.
14. Creemers, Jeroen HA, Ankur Ankan, **Kit CB Roes**, Gijs Schröder, Niven Mehra, Carl G Figgdor, I Jolanda M de Vries, and Johannes Textor. 2023. 'In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome', *Nature Communications*, 14: 2348.
15. Deforth, Manja, Charlotte Micheloud, **Kit C Roes**, and Leonhard Held. 2023. 'Combining evidence from clinical trials in conditional or accelerated approval', *Pharmaceutical Statistics*.
16. Benjamin Hofner, Elina Asikanius, Wolfgang Jacquet, Theodor Framke, Katrien Oude Rengerink, Lukas Aguirre Dávila, Maria Grünewald, Florian Klinglmüller, Martin Posch, Finbarr P Leacy, Thomas Lang, Armin Koch, Jörg Zinserling, **Kit Roes**. 2023. 'Vaccine development during a pandemic: General lessons for clinical trial design', *Statistics in Biopharmaceutical Research*: 1-13.
17. Janssen Daalen, Jules M, Marjan J Meinders, Federica Giardina, **Kit CB Roes**, Bas C Stunnenberg, Soania Mathur, Philip N Ainslie, Dick HJ Thijssen, and Bastiaan R Bloem. 2022. 'Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson's disease: study rationale and protocol', *BMC neurology*, 22: 1-12.
18. Joosten, Linda PT, Sander van Doorn, Peter M van de Ven, Bart TG Köhlen, Melchior C Nierman, Huiberdina L Koek, Martin EW Hemels, Menno V Huisman, Marieke Kruip, Laura M Faber, Nynke M Wiersma, Wim F Buding, Rob Fijnheer, Henk J Adriaansen, **Kit C Roes**, Arno W Hoes, Frans H Rutten, Geert-Jan Geersing. 2023. 'Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial', *Circulation*.
19. Kessels, Rob, Anne M May, Miriam Koopman, and **Kit CB Roes**. 2023. 'The Trial within Cohorts (TwICs) study design in oncology: experience and methodological reflections', *BMC Medical Research Methodology*, 23: 1-13.
20. Pateras, Konstantinos, **Kit CB Roes**, and Polychronis Kostoulas. 2023. 'Visualizing stability in studies: the moving average meta-analysis (MA2)', *arXiv preprint arXiv:2309.13640*.
21. **Roes, Kit**, and Janet Wittes. 2023. '14th Annual University of Pennsylvania Conference on statistical issues in clinical trials/subgroup analysis in clinical trials: Opportunities and challenges (morning panel discussion)', *Clinical Trials*: 17407745231175078.
22. Schootemeijer, Sabine, Nienke M de Vries, Eric A Macklin, **Kit CB Roes**, Hilde Joosten, Larsson Omberg,

- Alberto Ascherio, Michael A Schwarzschild, and Bastiaan R Bloem. 2023. 'The STEPWISE study: study protocol for a smartphone-based exercise solution for people with Parkinson's Disease (randomized controlled trial)', *BMC neurology*, 23: 323.
23. Simons, Michiel, **Kit CB Roes**, Marleen Kets, Barbara M Norquist, and Elizabeth M Swisher. 2023. 'TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol'.
 24. Rajeshwari Sridhara, Elizabeth Barksdale, Olga Marchenko, Qi Jiang, Yuki Ando, Erick Bloomquist, Michael Coory, Melissa Crouse, Evgeny Degtyarev, Theodor Framke, Boris Freidlin, David E Gerber, Thomas Gwise, Filip Josephson, Lorenzo Hess, Paul Kluetz, Daniel Li, Sumithra Mandrekar, Martin Posch, Khadija Rantell, Bohdana Ratitch, Andrew Raven, **Kit Roes**, Kaspar Rufibach, Sinan B Sarac, Richard Simon, Harpreet Singh, Marc Theoret, Andrew Thomson, Emmanuel Zuber, Yuan Li Shen, Richard Pazdur. 2023. 'Cancer Clinical Trials beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion', *Statistics in Biopharmaceutical Research*, 15: 444-49.
 25. Marloes Stam, Camiel A Wijngaarde, Bart Bartels, Fay-Lynn Asselman, Louise AM Otto, Laura E Habets, Ruben PA van Eijk, Bas M Middelkoop, H Stephan Goedee, Janke F de Groot, **Kit CB Roes**, Marja AGC Schoenmakers, Edward ES Nieuwenhuis, Inge Cuppen, Leonard H van den Berg, Renske I Wadman, W Ludo van der Pol. 2023. 'Randomized double-blind placebo-controlled crossover trial with pyridostigmine in spinal muscular atrophy types 2-4', *Brain Communications*, 5: fcac324.
 26. Steenbeek, Miranda P, Majke HD van Bommel, Christine B Peterson, Michiel Simons, **Kit CB Roes**, Marleen Kets, Barbara M Norquist, Elizabeth M Swisher, Rosella PMG Hermens, and Karen H Lu. 2023. 'TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol', *International Journal of Gynecologic Cancer*, 33.
 27. Storosum, Bram WC, Taina Mattila, Tamar D Wohlfarth, Christine C Gispén-de Wied, **Kit CB Roes**, Wim van den Brink, Lieuwe de Haan, Damiaan AJ Denys, and Jasper B Zantvoord. 2023. 'Gender differences in the response to antipsychotic medication in patients with schizophrenia: An individual patient data meta-analysis of placebo-controlled studies', *Psychiatry research*, 320: 114997.
 28. Storosum, Bram WC, Cedrine Steinz, Sem E Cohen, Taina Mattila, Wim van den Brink, **Kit Roes**, Lieuwe de Haan, Damiaan AJ Denys, and Jasper B Zantvoord. 2023. 'Ethnic differences in response to atypical antipsychotics in patients with schizophrenia: individual patient data meta-analysis of randomised placebo-controlled registration trials submitted to the Dutch Medicines Evaluation Board', *BJPsych open*, 9: e45.
 29. van Eijk, Ruben PA, Leonard H van den Berg, **Kit CB Roes**, Lu Tian, Tze L Lai, Lorene M Nelson, Chenyu Li, Anna Scowcroft, Jesus Garcia - Segovia, and Ying Lu. 2023. 'Hybrid controlled clinical trials using concurrent registries in Amyotrophic Lateral Sclerosis: A feasibility study', *Clinical Pharmacology & Therapeutics*, 114: 883-92.
 30. van Gelder, Marleen MHJ, Laura Rodwell, and **Kit CB Roes**. 2023. 'Designing observational studies by target trial emulation', *Nederlands Tijdschrift Voor Geneeskunde*, 167: D7702-D02.
 31. Willemse, Sean W, **Kit CB Roes**, Philip Van Damme, Orla Hardiman, Caroline Ingre, Monica Povedano, Naomi R Wray, Marleen Gijzen, Mirjam S De Pagter, and Koen C Demaegd. 2022. 'Lithium carbonate in amyotrophic lateral sclerosis patients homozygous for the C-allele at SNP rs12608932 in UNC13A: protocol for a confirmatory, randomized, group-sequential, event-driven, double-blind, placebo-controlled trial', *Trials*, 23: 978.
 32. Rajeshwari Sridhara, Olga Marchenko, Qi Jiang, Richard Pazdur, Martin Posch, Mary Redman, Yevgen Tymofeyev, Xiaoyun (Nicole) Li, Marc Theoret, Yuan Li Shen, Thomas Gwise, Lorenzo Hess, Michael Coory, Andrew Raven, Naoto Kotani, Kit Roes, Filip Josephson, Scott Berry, Richard Simon & Bruce Binkowitz (2022). Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion, *Statistics in Biopharmaceutical Research*, 14:3, 349_352, DOI: 10.1080/19466315.2021.1906743
 33. Rajeshwari Sridhara, Olga Marchenko, Qi Jiang, Richard Pazdur, Martin Posch, Scott Berry, Marc Theoret, Yuan Li Shen, Thomas Gwise, Lorenzo Hess, Andrew Raven, Khadija Rantell, Kit Roes, Richard Simon, Mary Redman, Yuan Ji & Cindy Lu (2022). Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion, *Statistics in Biopharmaceutical Research*, 14:3, 353_357, DOI: 10.1080/19466315.2021.1938204
 34. Vos JL, Raafs AG, van der Velde N, Germans T, Biesbroek PS, Roes K, Hirsch A, Heymans SRB, Nijveldt R. Comprehensive Cardiovascular Magnetic Resonance-Derived Myocardial Strain Analysis Provides Independent Prognostic Value in Acute Myocarditis. *J Am Heart Assoc*. 2022 Oct 4;11(19):e025106. doi: 10.1161/JAHA.121.025106. Epub 2022 Sep 21. PMID: 36129042. Janssen Daalen JM, Meinders MJ, Giardina F, Roes KCB, Stunnenberg BC, Mathur S, Ainslie PN, Thijssen DHJ, Bloem BR. Multiple N_of_1 trials to investigate hypoxia therapy in Parkinson's disease: study rationale and protocol. *BMC Neurol*. 2022 Jul 14;22(1):262. doi: 10.1186/s12883_022_02770_7. PMID: 35836147; PMCID: PMC9281145.
 35. Raafs AG, Vos JL, Henkens MTHM, Slurink BO, Verdonchot JAJ, Bossers D, Roes K, Gerretsen S, Knackstedt C, Hazebroek MR, Nijveldt R, Heymans SRB. Left Atrial Strain Has Superior Prognostic Value to Ventricular Function and Delayed Enhancement in Dilated Cardiomyopathy. *JACC Cardiovasc Imaging*. 2022 Jun;15(6):1015_1026. doi: 10.1016/j.jcmg.2022.01.016. Epub 2022 May 11. PMID: 35680209.
 36. Mitroiu M, Teerenstra S, Oude Rengerink K, Pétavy F, Roes KCB. Estimation of treatment effects in short term depression studies. An evaluation based on the ICH E9(R1) estimands framework. *Pharm Stat*. 2022 Sep;21(5):1037_1057. doi: 10.1002/pst.2214. Epub 2022 Jun 9. PMID: 35678545; PMCID: PMC9543408.
 37. van Eijk RPA, Roes KCB, van den Berg LH, Lu Y. Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials. *J Clin Epidemiol*. 2022 Jul;147:32_39. doi: 10.1016/j.jclinepi. 2022.03.009. Epub 2022 Mar 26. PMID: 35346783.
 38. Mensink FB, Ten Cate TJF, Damen SAJ, Roes K, Di Mario C, Singh V, Ali ZA, Skinner W, Artis A, Torguson R, Zhang C, Doros G, García-García HM, Mintz GS, Geuns RV, Waksman R. Near-infrared spectroscopy predicts events in men and women: Results from the Lipid Rich Plaque study. *Int J Cardiol Heart Vasc*. 2022 Mar 8;39:100985. doi: 10.1016/j.ijcha.2022.100985. PMID: 35281753; PMCID: PMC8914327.
 39. Stegeman R, Nijman M, Breur JMPJ, Groenendaal F, Haas F, Derks JB, Nijman J, van Beynum IM, Taverne YJH, Bogers AJJC, Helbing WA, de Boode WP, Bos AF, Berger RMF, Accord RE, Roes KCB, de Wit GA, Jansen NJG, Benders MJNL; CRUCIAL trial consortium. CeRebrUm and CardIac Protection with Allopurinol in Neonates with Critical Congenital Heart Disease Requiring Cardiac Surgery with Cardiopulmonary Bypass (CRUCIAL): study protocol of a phase III, randomized, quadruple-blinded, placebo-controlled, Dutch multicenter trial. *Trials*. 2022 Feb 23;23(1):174. doi: 10.1186/s13063_022_06098_y. PMID: 35197082; PMCID: PMC8867620.
 40. Daltzakis A, van den Bor R, Jonker MA, Roes KCB, van Tinteren H. Estimation and expected sample size in Simon's two stage designs that stop as early as possible. *Pharm Stat*. 2022 Feb 22. doi: 10.1002/pst.2200. Epub ahead of print. PMID: 35191174.
 41. Kliest T, Van Eijk RPA, Al-Chalabi A, Albanese A, Andersen PM, Amador MDM, Bråthen G, Brunaud Danel V, Brylev L, Camu W, De Carvalho M, Cereda C, Cetin H, Chayverri D, Chiò A, Corcia P, Couratier P, De Marchi F, Desnuelle C, Van Es MA, Esteban J, Filosto M, García Redondo A, Grosskreutz J, Hanemann CO, Holmøy T, Høyer H, Ingre C, Koritnik B, Kuzma_Kozakiewicz M, Lambert T, Leigh PN, Lunetta C, Mandrioli J, Mcdermott CJ, Meyer T, Mora JS, Petri S, Povedano M, Reviers E, Riva N, Roes KCB, Rubio MÁ, Salachas F, Sarafov S, Sorarü G, Stevic Z, Svenstrup K, Møller AT, Turner MR, Van Damme P, van Leeuwen LAG, Varona L, Vázquez Costa JF, Weber M, Hardiman O, Van Den Berg LH. Clinical trials in pediatric ALS: a TRICALS feasibility study. *Amyotroph Lateral Scler Frontotemporal Degener*. 2022 Feb 16:1_8. doi: 10.1080/21678421.2021.2024856. Epub ahead of print. PMID: 35172656.
 42. van Eijk RPA, Roes KCB, de Greef van der Sandt I, van den Berg LH, Lu Y. Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or ot to Combine_That is the Estimand. *Clin Pharmacol Ther*. 2022 Jan 25. doi: 10.1002/cpt.2533. Epub ahead of print. PMID: 35076930.

43. van Poelgeest R, Schrijvers A, Boonstra A, Roes K. Medical Specialists' Perspectives on the Influence of Electronic Medical Record Use on the Quality of Hospital Care: Semistructured Interview Study. *JMIR Hum Factors*. 2021 Oct 27;8(4):e27671. doi: 10.2196/27671. PMID: 34704955.
44. van Eijk RPA, Beelen A, Kruitwagen ET, Murray D, Radakovic R, Hobson E, Knox L, Helleman J, Burke T, Rubio Pérez MA, Reviers E, Genge A, Steyn FJ, Ngo S, Eaglesham J, Roes KCB, van den Berg LH, Hardiman O, McDermott CJ. A Road Map for Remote Digital Health Technology for Motor Neuron Disease. *J Med Internet Res*. 2021 Sep 22;23(9):e28766. doi: 10.2196/28766. PMID: 34550089.
45. Müller AR, Zinkstok JR, Rommelse NNJ, van de Ven PM, Roes KCB, Wijburg FA, de Rooij_Askes E, Linders C, Boot E, van Eeghen AM. Methylphenidate for attention_deficit/hyperactivity disorder in patients with Smith_Magenis syndrome: protocol for a series of N_of_1 trials. *Orphanet J Rare Dis*. 2021 Sep 8;16(1):380. doi:10.1186/s13023_021_02003_z. PMID: 34496899; PMCID: PMC8424817.
46. van Eijk RPA, Nikolakopoulos S, Roes KCB, Kendall L, Han SS, Lavrov A, Epstein N, Kliest T, de Jongh AD, Westeneng HJ, Al_Chilabi A, Van Damme P, Hardiman O, Shaw PJ, McDermott CJ, Eijkemans MJC, van den Berg LH. Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order. *Neurology*. 2021 Sep 14;97(11):528_536. doi: 10.1212/WNL.0000000000012545. Epub 2021 Jul 27. PMID: 34315786; PMCID: PMC8456357.
47. Kersten RFMR, Öner FC, Arts MP, Mitroiu M, Roes KCB, de Gast A, van Gaalen SM. Letter to the editor regarding "Two_year results of a double_blind multicenter randomized controlled non_inferiority trial of polyetheretherketone (PEEK) versus silicon nitride spinal fusion cages in patients with symptomatic degenerative lumbar disc disorders". *J Spine Surg*. 2021 Jun;7(2):249_251. doi:10.21037/jss_21_6. PMID: 34296041; PMCID: PMC8261572.
48. Sarraimi_Foroushani A, Lassila T, MacRaild M, Asquith J, Roes KCB, Byrne JV, Frangi AF. In_silico trial of intracranial flow diverters replicates and expands insights from conventional clinical trials. *Nat Commun*. 2021 Jun 23;12(1):3861. doi: 10.1038/s41467_021_23998_w. PMID: 34162852; PMCID: PMC8222326.
49. Pateras K, Nikolakopoulos S, Roes KCB. Combined assessment of early and late_phase outcomes in orphan drug development. *Stat Med*. 2021 May 30;40(12):2957_2974. doi: 10.1002/sim.8952. Epub 2021 Apr 4. PMID: 33813759; PMCID: PMC8252448.
50. van Eijk RPA, de Jongh AD, Nikolakopoulos S, McDermott CJ, Eijkemans MJC, Roes KCB, van den Berg LH. An old friend who has overstayed their welcome: the ALSFRS_R total score as primary endpoint for ALS clinical trials. *Amyotroph Lateral Scler Frontotemporal Degener*. 2021 May;22(3_4):300_307. doi: 10.1080/21678421.2021.1879865. Epub 2021 Feb 2. PMID: 33527843.
51. Müller AR, Brands MMMG, van de Ven PM, Roes KCB, Cornel MC, van Karnebeek CDM, Wijburg FA, Daams JG, Boot E, van Eeghen AM. Systematic Review of N_of_1 Studies in Rare Genetic Neurodevelopmental Disorders: The Power of 1. *Neurology*. 2021 Mar 16;96(11):529_540. doi: 10.1212/WNL.0000000000011597. Epub 2021 Jan 27. PMID: 33504638; PMCID: PMC8032375.
52. Ramjith J, Roes KCB, Zar HJ, Jonker MA. Flexible modelling of risk factors on the incidence of pneumonia in young children in South Africa using piece_wise exponential additive mixed modelling. *BMC Med Res Methodol*. 2021 Jan 11;21(1):17. doi: 10.1186/s12874_020_01194_6. PMID: 33430789; PMCID: PMC7802241.
53. Kersten RFMR, Öner FC, Arts MP, Mitroiu M, Roes KCB, de Gast A, van Gaalen SM. The SNAP Trial: 2_Year Results of a Double_Blind Multicenter Randomized Controlled Trial of a Silicon Nitride Versus a PEEK Cage in Patients After Lumbar Fusion Surgery. *Global Spine J*. 2021 Jan 7:2192568220985472. doi: 10.1177/2192568220985472. Epub ahead of print. PMID: 33406905.
54. Maas RPPWM, Ramjith J, Klockgether T, Roes KCB, van de Warrenburg BPC. A word of hope for ataxia trials in COVID_19 time and beyond. *J Neurol*. 2021 Jul;268(7):2343_2345. doi: 10.1007/s00415_020_10231_9. Epub 2020 Sep 22. PMID: 32964331; PMCID: PMC7508233.
55. Pateras K, Nikolakopoulos S, Roes KCB. Prior distributions for variance parameters in a sparse_event meta_analysis of a few small trials. *Pharm Stat*. 2021 Jan;20(1):39_54. doi: 10.1002/pst.2053. Epub 2020 Aug 6. PMID: 32767452; PMCID: PMC7818503.
56. Mitroiu M, Oude Rengerink K, Teerenstra S, Pétavy F, Roes KCB. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels? *Trials*. 2020 Jul 23;21(1):671. doi: 10.1186/s13063_020_04546_1. PMID: 32703247; PMCID: PMC7376663.
57. van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, Weber M, Ingre C, Corcia P, Povedano M, Reviers E, van Es MA, Al_Chilabi A, Hardiman O, van den Berg LH. TRICALS: creating a highway toward a cure. *Amyotroph Lateral Scler Frontotemporal Degener*. 2020 Nov;21(7_8):496_501. doi: 10.1080/21678421.2020.1788092. Epub 2020 Jul 9. PMID: 32643415.
58. Coelingh Bennink HJT, Egberts JFM, Mol JA, Roes KCB, van Diest PJ. Breast Cancer and Major Deviations of Genetic and Gender_related Structures and Function. *J Clin Endocrinol Metab*. 2020 Sep 1;105(9):dgaa404. doi:10.1210/clinem/dgaa404. PMID: 32594127.
59. Geersing GJ, Hendriksen JMT, Zuithoff NPA, Roes KC, Oudega R, Takada T, Schutgens REG, Moons KGM. Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial. *PLoS Med*. 2020 Jun 26;17(6):e1003142. doi: 10.1371/journal.pmed.1003142. PMID: 32589630; PMCID: PMC7319277.
60. Oude Rengerink K, Mitroiu M, Teerenstra S, Pétavy F, Roes KCB. Rethinking the intention_to_treat principle: one size does not fit all. *J Clin Epidemiol*. 2020 Sep;125:198_200. doi: 10.1016/j.jclinepi.2020.09.002.
61. Vreman RA, Belitser SV, Mota ATM, Hövels AM, Goettsch WG, Roes KCB, LeufkensHGM, Mantel_Teeuwisse AK. Efficacy gap between phase II and subsequent phase III studies in oncology. *Br J Clin Pharmacol*. 2020 Feb 7. doi: 10.1111/bcp.14237. [Epub ahead of print] PubMed PMID: 32034790.
62. Blankestijn PJ, Fischer KI, Barth C, Cromm K, Canaud B, Davenport A, Grobbee DE, Hegbrant J, Roes KC, Rose M, Strippoli GF, Vernooij RW, Woodward M, de Wit GA de, Bots ML. Benefits and harms of high_dose haemodiafiltration versus high_flux haemodialysis: the comparison of high_dose haemodiafiltration with high_flux haemodialysis (CONVINCE) trial protocol. *BMJ Open*. 2020 Feb 5;10(2):e033228. doi: 10.1136/bmjopen.2019_033228. PubMed PMID: 32029487.
63. Collignon O, Gartner C, Haidich AB, James Hemmings R, Hofner B, Pétavy F, Posch M, Rantell K, Roes K, Schiel A. Current Statistical Considerations and Regulatory Perspectives on the Planning of Confirmatory Basket, Umbrella, and Platform Trials. *Clin Pharmacol Ther*. 2020 Feb 4. doi: 10.1002/cpt.1804. [Epub ahead of print] Review. PubMed PMID: 32017052.
64. Luiten JD, Voogd AC, Luiten EJT, Broeders MJM, Roes KCB, Tjan_Heijnen VCG, Duijm LEM. Recall and Outcome of Screen_detected Microcalcifications during 2 Decades of Mammography Screening in the Netherlands National Breast Screening Program. *Radiology*. 2020 Mar;294(3):528_537. doi: 10.1148/radiol.2020191266. Epub 2020 Jan 28. PubMed PMID: 31990268.
65. Joosten LPT, van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL, Hemels MEW, Huisman MV, Roes KC, van den Bor RM, Buding WF, Rutten FH, Geersing GJ. Safety of switching from vitamin K antagonist to non_vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL_AF randomised controlled trial. *BMJ Open*. 2019 Dec 29;9(12):e032488. doi: 10.1136/bmjopen.2019_032488. PubMed PMID: 31888928; PubMed Central PMCID: PMC6937027.
66. Pétavy F, Guizzaro L, Antunes Dos Reis I, Teerenstra S, Roes KCB. Beyond "Intent_to_treat" and "Per protocol": Improving assessment of treatment effects in clinical trials through the specification of an estimand. *Br J Clin Pharmacol*. 2019 Dec 27. doi: 10.1111/bcp.14195. [Epub ahead of print] PubMed PMID: 31883123.
67. van der Plas RM, Hoefnagel MHN, Hillege HL, Roes KCB. Pragmatic rules for comparability of biological medicinal products. *Biologicals*. 2020 Jan;63:97_100. doi: 10.1016/j.biologicals.2019.11.002. Epub 2019 Dec 11. PubMed PMID: 31836276.
68. Gaasterland CMW, van der Weide MCJ, Roes KCB, van der Lee JH. Goal attainment scaling as an outcome measure in rare disease trials: a conceptual proposal for validation. *BMC Med Res Methodol*. 2019 Dec 4;19(1):227. doi: 10.1186/s12874_019_0866_x. PubMed PMID: 31801463; PubMed Central PMCID: PMC6894223.

69. Houwert RM, Beks RB, Dijkgraaf MGW, Roes KCB, Öner FC, Hietbrink F, Leenen LPH, Groenwold RHH. Study methodology in trauma care: towards question_based study designs. *Eur J Trauma Emerg Surg*. 2019 Oct 29. doi: 10.1007/s00068_019_01248_5. [Epub ahead of print] PubMed PMID: 31664467.
70. van Eijk RPA, Nikolakopoulos S, Roes KCB, Middelkoop BM, Ferguson TA, Shaw PJ, Leigh PN, Al-Chalabi A, Eijkemans MJC, van den Berg LH. Critical design considerations for time_to_event endpoints in amyotrophic lateral sclerosis clinical trials. *J Neurol Neurosurg Psychiatry*. 2019 Dec;90(12):1331_1337. doi: 10.1136/jnnp_2019_320998. Epub 2019 Jul 10. PubMed PMID: 31292200; PubMed Central PMCID: PMC6902062.
71. Tanniou J., Sanne C. Smid, Ingeborg van der Tweel, Steven Teerenstra, Kit C.B. Roes (2019). Level of evidence for promising subgroup findings: the case of trends and multiple subgroups. *Statistics in Medicine*, <https://doi.org/10.1002/sim.8133>
72. Arends J., Roland D Thijs, Therese Gutter, Constantin Ungureanu, Pierre J.M. Cluitmans, Hans van van Dijk, Judith Van Andel, In Tan, Al de de Weerd, Ben Vledder, Wytse Hofstra, Richard Lazerou, Ghislaine van van Thiel, Kit Roes, and Frans Leijten (2018). Multimodal nocturnal seizure detection in a residential care setting: a long_term prospective trial. *Neurology*. Epub ahead of print. doi:10.1212/WNL.00000000000006545.
73. de Windt T.S., S.L. Niemansburg, L.A. Vonk, J.M. van Delden, K.C.B. Roes, W.J.A. Dhert, D.B.F. Saris, A.L. Bredenoord (2018). Ethics in musculoskeletal regenerative medicine; guidance in choosing the appropriate comparator in clinical trials. *Osteoarthritis and Cartilage* (2018), <https://doi.org/10.1016/j.joca.2018.08.022>.
74. Rozemeijer R., Mera Stein, Michiel Voskuil, MD, Rutger van den Bor, Peter Frambach, Bruno Pereira, Stefan Koudstaal, Geert E. Leenders, Leo Timmers, Saskia Z. Rittersma, Adriaan O. Kraaijeveld, Pierfrancesco Agostoni, Kit Roes, Pieter A. Doevendans, Pieter Stella (2018). Randomized All_Comers Evaluation of a Permanent Polymer Zotarolimus_Eluting Stent Versus a Polymer_Free Amphilimus_Eluting Stent: (ReCre8) A Multicenter, Non_Inferiority Trial. *Circulation*, 22 Sep 2018. Epub ahead of print.
75. Mitroiu M., Katrien Oude Rengerink, Caridad Pontes, Arantxa Sancho, Roser Vives, Stella Pesiou, Manel Fontanet, Ferran Torres, Stavros Nikolakopoulos, Konstantinos Pateras, Gerd Rosenkranz, Martin Posch, Susanne Urach, Robin Ristl, Armin Koch, Loukia Spineli, Johanna H. van der Lee, Kit CB Roes. Applicability and added value of novel methods to improve drug development in rare diseases. *Orphanet Journal of Rare Diseases*.
76. Day S., Anneliene Hechtelt Jonker; Lilian Pek Lian Lau, Ralf Dieter Hilgers, Ilan Irony, Kristina Larsson; Kit C.B. Roes, Nigel Stallard. (2018). Recommendations for the design of small population clinical trials. *Orphanet Journal of Rare Diseases*. 13:195. https://doi.org/10.1186/s13023_018_0931_2.
77. Pontes C., Manel Fontanet, Roser Vives, Arantxa Sancho, Mònica Gómez_Valent, José Ríos, Rosa Morros, Jorge Martinalbo, Martin Posch, Armin Koch, Kit C.B. Roes, Katrien Oude Rengerink, Josep Torrent_Farnell, Ferran Torres (2018). Evidence supporting regulatory_decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. *Orphanet Journal of Rare Diseases*.
78. Gaasterland C.M.W., M.C. Jansen_van der Weide, E. Vroom, K. Leeson_Beevers, M. Kaatee, R. Kaczmarek, B. Bartels, W.L. van der Pol, K.C.B. Roes, J.H. van der Lee (2018). The POWER_tool: Recommendations for involving patient representatives in choosing relevant outcome measures during rare disease clinical trial design. *Health Policy*, <https://doi.org/10.1016/j.healthpol.2018.09.011>.
79. Jansen_van der Weide M.C., Charlotte M. W. Gaasterland, Kit C. B. Roes, Caridad Pontes, Roser Vives, Arantxa Sancho, Stavros Nikolakopoulos, Eric Vermeulen,, Johanna H. van der Lee (2018). Rare disease registries: potential applications towards impact on development of new drug treatments. *Orphanet Journal of Rare Diseases*, 13:154, https://doi.org/10.1186/s13023_018_0836_0.
80. Leijten, F.S.S., van Andel, J., Ungureanu, C., Arends, J., Tan, F., van Dijk, J., Petkov, G., Kalitzin, S., Gutter, T., de Weerd, A., Vledder, B., Thijs, R., van Thiel, G., Roes, K., Hofstra, W., Lazerou, R., Cluitmans, P., Ballieux, M., de Groot, M. & the Dutch TeleEpilepsy Consortium (2018). Multimodal seizure detection: A review.: *Epilepsia*. 59, p. 42_47 6 p.
81. Brakenhoff Timo B., Kit C. B. Roes, Karel G. M. Moons and Rolf H. H. Groenwold (2018). Outlier classification performance of risk adjustment methods when profiling multiple providers. *BMC Medical Research Methodology* (2018) 8:54 https://doi.org/10.1186/s12874_018_0510_1
82. Brakenhoff TB, KCB Roes and S Nikolakopoulos (2018). Bayesian sample size re_estimation using power priors. *Statistical Methods in Medical Research*. <https://doi.org/10.1177/0962280218772315>
83. van Stiphout F., J. E. F. Zwart_van Rijkom, J. Versmissen, H. Koffijberg, J. E. C. M. Aarts, I. H. van der Sijs, T. van Gelder , R. A. de Man, C. B. Roes, A. C. G. Egberts and E. W. M. ter Braak (2018). Effects of training physicians in electronic prescribing in the outpatient setting on clinical, learning and behavioural outcomes: a cluster randomized trial. *Br J Clin Pharmacol* (2018), 84, 1187–1197.
84. Pateras K, Nikolakopoulos S, Mavridis D, Roes KCB (2018). Interval estimation of the overall treatment effect in a meta_analysis of a few small studies with zero events. *Contemp Clin Trials Commun*. 2018 Jan 9;9:98_107. doi:10.1016/j.conctc.2017.11.012.
85. Roes KCB, van der Zande ISE, van Smeden M, van der Graaf R (2018). Towards an appropriate framework to facilitate responsible inclusion of pregnant women in drug development programs. *Trials*. 2018 Feb 20;19(1):123. doi: 10.1186/s13063_018_2495_9.
86. van den Bor RM, Grobbee DE, Oosterman BJ, Vaessen PWJ, Roes KCB (2017). Predicting enrollment performance of investigational centers in phase III multi_center clinical trials. *Contemp Clin Trials Commun*. 2017 Jul 20;7:208_216. doi:10.1016/j.conctc.2017.07.004.
87. Andel, Judith, Constantin Ungureanu, Johan Arends, Francis Tan, Johannes Van Dijk, George Petkov, Stiliyan Kalitzin, Thea Gutter, Al de Weerd, Ben Vledder, Roland Thijs, Ghislaine van Thiel, Kit Roes, and Frans Leijten. (2017). Multimodal, automated detection of nocturnal motorseizures at home: Is a reliable seizure detector feasible? *Epilepsia Open*, 2(4):424–431, 2017. doi: 10.1002/epi4.12076
88. Pateras K., Nikolakopoulos S. and Roes K.C.B (2017). Data generating models of dichotomous outcomes: Heterogeneity in simulation studies for a random_effects meta_analysis. Accepted for publication, *Stat in Medicine*.
89. Nikolakopoulos S., I. van der Tweel and K.C.B. Roes (2017). Dynamic borrowing through empirical power priors that control type I error. Accepted for publication, *Biometrics*.
90. Hoeven LRV, Bruijne MC, Kemper PF, Koopman MMW, Rondeel JMM, Leyte A, Koffijberg H, Janssen MP, Roes KCB. Validation of multisource electronic health record data: an application to blood transfusion data. *BMC Med Inform Decis Mak*. 2017 Jul 14;17(1):107. doi: 10.1186/s12911_017_0504_7.
91. Roes K. Editorial on special topic ISCB 2015: "Clinical research design, rare diseases, and personalized medicine". *Biom J*. 2017 Jul;59(4):607_608. doi: 10.1002/bimj.201700065.
92. Tanniou J, van der Tweel I, Teerenstra S, Roes KCB. Estimates of subgroup treatment effects in overall nonsignificant trials: To what extent should we believe in them? *Pharm Stat*. 2017 Jul;16(4):280_295. doi: 10.1002/pst.1810. Epub 2017 May 15.
93. van den Bor RM, Vaessen PWJ, Oosterman BJ, Zuihthoff NPA, Grobbee DE, Roes KCB. A computationally simple central monitoring procedure, effectively applied to empirical trial data with known fraud. *J Clin Epidemiol*. 2017 Jul;87:59_69. doi: 10.1016/j.jclinepi.2017.03.018. Epub 2017 Apr 12.
94. Novianti PW, Jong VL, Roes KC, Eijkemans MJ. Meta_analysis approach as a gene selection method in class prediction: does it improve model performance? A case study in acute myeloid leukemia. *BMC Bioinformatics*. 2017 Apr 11;18(1):210. doi: 10.1186/s12859_017_1619_7. PMC5387259.
95. van Poelgeest R, van Groningen JT, Daniels JH, Roes KC, Wiggers T, Wouters MW, Schrijvers G. Level of Digitization in Dutch Hospitals and the Lengths of Stay of Patients with Colorectal Cancer. *J Med Syst*. 2017 May;41(5):84. doi:10.1007/s10916_017_0734_3. Epub 2017 Apr 8.
96. Cellissen E, Franx A, Roes KC. Use of quality indicators by obstetric caregivers in the Netherlands: A descriptive study. *Eur J Obstet Gynecol Reprod Biol*. 2017 Apr;211:177_181. doi: 10.1016/j.ejogrb.2017.02.016. Epub 2017 Feb 28.
97. Roes KC. A framework: make it useful to guide and improve practice of clinical trial design in smaller populations. *BMC Med*. 2016 Nov 25;14(1):195.

98. Hilgers RD, Roes K, Stallard N; IDEAl, Asterix and InSPIRe project groups. Directions for new developments on statistical design and analysis of small population group trials. *Orphanet Journal of Rare Diseases*. 2016 Jun 14;11(1):78. doi: 10.1186/s13023-016-0464-5. PMID: 27301273.
99. Nikolakopoulos, S., Roes, K.C.B., Tweel, I. van der (2016). Sequential designs with small samples: Evaluation and recommendations for normal responses. *Statistical Methods in Medical Research*, 2016, June 24. DOI: 10.1177/0962280216653778. [Epub ahead of print].
100. Reynolds, Robert F.; Kurz, Xavier; de Groot, Mark C H; Schlienger, Raymond G.; Grimaldi, Bensouda, Lamiae; Tcherny-Lessenot, Stephanie; Klungel, Olaf H.; & 67 others of work_package 2 of PROTECT. The IMI PROTECT project : Purpose, organizational structure, and procedures. *Pharmacoepidemiology and Drug Safety*, Vol. 25 Suppl 1, 01.03.2016, p. 5_10.
101. De Groot, Mark C H; Candore, Gianmario; Uddin, Md Jamal; Souverein, Patrick C.; Ali, M. Sanni; Belitser, Svetlana V.; Huerta, Consuelo; Groenwold, Rolf H H; Alvarez, Yolanda; Slattery, Jim; Korevaar, Joke; Hoes, Arno W.; Roes, Kit C B; de Boer, Anthonius; Douglas, Ian J.; Schlienger, Raymond G.; Reynolds, Robert; Klungel, Olaf H.; Gardarsdottir, Helga. Case-only designs for studying the association of antidepressants and hip or femur fracture. *Pharmacoepidemiology and Drug Safety*, Vol. 25 Suppl 1, 01.03.2016, p. 103_113.
102. Tanniou J., Ingeborg van der Tweel, Steven Teerenstra, Kit C. B. Roes: Subgroup analyses in confirmatory clinical trials: Time to be specific about their purposes. *BMC Medical Research Methodology* 12/2016; 16(1). DOI:10.1186/s12874-016-0122-6
103. Uddin J., Rolf H. H. Groenwold, Mohammed Sanni Ali, Anthonius de Boer, Kit C. B. Roes, Muhammad A. B. Chowdhury, Olaf H. Klungel: Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. *International Journal of Clinical Pharmacy* 04/2016; DOI:10.1007/s11096-016-0299-0
104. Sanni M Ali, Rolf H H Groenwold, Svetlana V Belitser, Patrick C Souverein, Elisa Martin, Nicole M Gatto, Consuelo Huerta, Helga Gardarsdottir, Kit C B Roes, Arno W Hoes, Anthonius de Boer, Olaf H Klungel: Methodological comparison of marginal structural model, time_varying Cox regression, and propensity score methods: The example of antidepressant use and the risk of hip fracture. *Pharmacoepidemiology and Drug Safety* 03/2016; 25 Suppl 1:114_121. DOI:10.1002/pds.3864
105. Uddin Jamal, Rolf H H Groenwold, Anthonius de Boer, Ana S M Afonso, Paola Primatesta, Claudia Becker, Svetlana V Belitser, Arno W Hoes, Kit C B Roes, Olaf H Klungel: Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long_acting beta2_agonist use and the risk of myocardial infarction. *Pharmacoepidemiology and Drug Safety* 03/2016; 25 Suppl 1:132_141. DOI:10.1002/pds.3860
106. de Groot Mark C H, Gianmario Candore, Md Jamal Uddin, Patrick C Souverein, M Sanni Ali, Svetlana V Belitser, Consuelo Huerta, Rolf H H Groenwold, Yolanda Alvarez, Jim Slattery, Joke Korevaar, Arno W Hoes, Kit C B Roes, Anthonius de Boer, Ian J Douglas, Raymond G Schlienger, Robert Reynolds, Olaf H Klungel, Helga Gardarsdottir: Case-only designs for studying the association of antidepressants and hip or femur fracture. *Pharmacoepidemiology and Drug Safety* 03/2016; 25 Suppl 1:103_113. DOI:10.1002/pds.3850
107. Jong Victor L, Putri W Novianti, Kit CB Roes, Marinus J.C. Eijkemans: Selecting a classification function for class prediction with gene expression data. *Bioinformatics* 02/2016; DOI:10.1093/bioinformatics/btw034 van Hoeven Loan R, Mart P Janssen, Kit C B Roes, Hendrik Koffijberg: Aiming for a representative sample: Simulating random versus purposive strategies for hospital selection. *BMC Medical Research Methodology* 10/2015; 15(1):90. DOI:10.1186/s12874-015-0089-8
108. van den Bor R.M., Bas J. Oosterman, Martinus B. Oostendorp, Diederick E. Grobbee, Kit C. B. Roes: Efficient Source Data Verification Using Statistical Acceptance Sampling: A Simulation Study. *Therapeutic Innovation and Regulatory Science* 09/2015; 50(1). DOI:10.1177/2168479015602042
109. Uddin Jamal, Rolf H. H. Groenwold, Mohammed Sanni Ali, Gianmario Candore, Mark C. H. de Groot, Patrick C. Souverein, Yolanda Alvarez, Svetlana V. Belitser, Arno W. Hoes, Anthonius de Boer, Kit C. B. Roes, Olaf H. Klungel, Helga Gardarsdottir: Impact of Violations of the Assumptions of the Self-controlled Case Series Design in Pharmacoepidemiological Studies: An Example of Antidepressants Use and the Risk of Hip Fracture. *Pharmacoepidemiology and Drug Safety* 09/2015; 24:2_3.
110. Novianti P.W., van der Tweel I., Jong V.L., Roes K.C.B., Eijkemans M.J.C. (2015). An Application of Sequential Meta-Analysis to Gene Expression Studies. *Cancer Informatics* 14(Suppl 5):1_10 • September 2015.
111. Bor, R.M., Oosterman B.J., Oostendorp M.B., Roes K.C.B. (2015). Efficient Source Data Verification Using Statistical Acceptance Sampling: A Simulation Study. *Therapeutic Innovation and Regulatory Science*, September 2015.
112. Zegers M., Hesselink G., Roes K.C.B., Wollersheim H. (2015). A proactive approach to risks: from responding to leading (in Dutch). *Nederlands tijdschrift voor geneeskunde* 159:A8940 • July 2015.
113. Eijkemans M.J.C., van der Wal W., Reijnders L.J., Roes K.C.B., van Waalwijk van Doorn-Khosrovani S., Pelletier C., Magestro M., Zonnenberg B. (2015). Long-term Follow-up Assessing Renal Angiomyolipoma Treatment Patterns, Morbidity, and Mortality: An Observational Study in Tuberous Sclerosis Complex Patients in the Netherlands. *American Journal of Kidney Diseases* 41 • July 2015.
114. Van Stiphout F., Zwart van Rijkom J.E.F., Aarts J.C.M., Koffijberg H., Klarenbeek-de Jonge E., Krulder M., Roes K.C.B., Egberts A.G., ter Braak, E.W.M.T. (2015). MEDUCATE trial: Effectiveness of an intensive EDUCational intervention for IT-mediated MEDication management in the outpatient clinic _ study protocol for a cluster randomized controlled trial. *Trials* 05/2015; 16(1). DOI:10.1186/s13063-015-0744-8.
115. Novianti P.W., Jong V.L., Roes K.C.B., Eijkemans M.J.C. (2015). Factors affecting the accuracy of a class prediction model in gene expression data. *BMC Bioinformatics* 06/2015; 16(199). DOI:10.1186/s12859-015-0610-4.
116. Schuit E., Roes K.C.B., Mol B.W., Groenwold R.H. (2015). Meta-analyses triggered by previous (false_)significant findings: problems and solutions. *Systematic Reviews* 04/2015; 4(1):57. DOI:10.1186/s13643-015-0048-9.
117. Jong V.L., Novianti P.W., Roes K.C.B., Eijkemans M.J.C. (2015). Exploring homogeneity of correlation structures of gene expression datasets within and between etiological disease categories. *Statistical Applications in Genetics and Molecular Biology* 12/2014; 13(6):717_32. DOI:10.1515/sagmb-2014-0003.
118. Ali, M.S., Groenwold, R.H.H., Pestman, W.R., Belitser, S., Hoes, A.W., Boer, A. de, Roes, K.C.B. & Klungel, O.H. (2014). Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. *Journal of Clinical Epidemiology* 11/2014; 68(2). DOI:10.1016/j.jclinepi.2014.08.011.
119. Uddin, M.J., Groenwold, R.H.H., van der Staa T., Boer, A., Belitser, S., Hoes, A.W., de, Roes, K.C.B. & Klungel, O.H. (2014). Performance of prior event rate ratio adjustment method in pharmacoepidemiology: A simulation study. *Pharmacoepidemiology and Drug Safety* 11/2014; 24(5). DOI:10.1002/pds.3724
120. Ali, M.S., Groenwold, R.H.H., Pestman, W.R., Belitser, S.V., Roes, K.C.B., Hoes, A.W., Boer, A. de & Klungel, O.H. (2014). Propensity score balance measures in pharmacoepidemiology: a simulation study. *Pharmacoepidemiology and Drug Safety*, 23(8), 802_811.
121. Ali, M.S., Uddin, M.J., Groenwold, R.H.H., Pestman, W.R., Belitser, S., Hoes, A.W., Boer, A. de, Roes, K.C.B. & Klungel, O.H. (2014). Quantitative falsification of instrumental variables assumption using balance measures. *Epidemiology*, 25(5), 770_772.
122. van Andel J., Leijten F., Roes K.C.B., Arends J.(2014). Usefulness of movement and heart rate as physiological signals to detect nocturnal epileptic seizures. *Clinical Neurophysiology* 06/2014; 125:S259_S260. DOI:10.1016/S1388-2457(14)50848_6
123. Boessen, R., Heerspink, H.J., Zeeuw, D. de, Grobbee, D.E., Groenwold, R.H.H. & Roes, K.C.B. (2014). Improving clinical trial efficiency by biomarker-guided patient selection. *Trials*, 2(15 (1)).
124. Kersten, R.F.M.R., Gaalen, S.M. van, Arts, M.P., Roes, K.C.B., Gast, A de, Corbin, T.P. & Öner, F.C. (2014). The SNAP trial: a double blind multi-center randomized controlled trial of a silicon nitride versus a PEEK cage in transforaminal lumbar interbody fusion in patients with symptomatic degenerative lumbar

- disc disorders: study protocol. *BMC Musculoskeletal Disorders* [E], 15, 57.
125. Nikolakopoulos, S., Roes, K.C.B., Lee, J.H. van der & Tweel, I. van der (2014). Sample size calculations in pediatric clinical trials conducted in an ICU: a systematic review. *Trials*, 15(1), 274.
 126. Novianti, P.W., Roes, K.C.B. & Eijkemans, M.J.C. (2014). Evaluation of gene expression classification studies: factors associated with classification performance. *PLoS ONE* [E], 9(4), e96063.
 127. Ottens, T.H., Dieleman, J.M., Sauër, A.M., Peelen, L.M., Nierich, A.P., Groot, W.J., Nathoe, H.M., Buijsrogge, M.P., Kalkman, C.J., Bredee, J.J., Buhre, W.F., Herwerden, L.A. van, Klarenbosch, J. van, Moons, K.G.M., Numan, S.C., Roes, K.C.B., Slooter, A.J., et al., X, DECS, GROUP & Dijk, D. van (2014). Effects of dexamethasone on cognitive decline after cardiac surgery: a randomized clinical trial. *Anesthesiology*, 121(3), 492–500.
 128. Schmidt, A.F., Groenwold, R.H.H., Knol, M.J., Hoes, A.W., Nielen, M., Roes, C.B., Boer, A. de & Klungel, O.H. (2014). Exploring interaction effects in small samples increases rates of false_positive and false_negative findings: results from a systematic review and simulation study. *Journal of Clinical Epidemiology*, 67(7), 821–829.
 129. Smorenburg, A.J., Oosterman, B.J., Grobbee, D.E., Bonten, M.J.M. & Roes, K.C.B. (2014). Effects of recruitment strategies and demographic factors on inclusion in a large scale vaccination trial in adults 65 years and older. *Vaccine*, 14(00274).
 130. Schmidt AF, Groenwold RH, van Delden JJ, van der Does Y, Klungel OH, Roes K.C.B., Hoes AW, van der Graaf R. (2014). Justification of exclusion criteria was underreported in a review of cardiovascular trials. *Journal of Clinical Epidemiology* 03/2014; DOI:10.1016.
 131. Vink EE, de Beus E, de Jager RL, Voskuil M, Spiering W, Vonken EJ, de Wit GA, Roes K.C.B., Bots ML, Blankestijn PJ. (2014). The effect of renal denervation added to standard pharmacologic treatment versus standard pharmacologic treatment alone in patients with resistant hypertension: Rationale and design of the SYMPATHY trial. *Am Heart J*. 2014 Mar;167(3):308–314.e3. doi: 10.1016/j.ahj.2013.11.010.
 132. Ng CG, Boks MP, Roes K.C.B., Zainal NZ, Sulaiman AH, Tan SB, de Wit NJ. (2014). Rapid response to methylphenidate as an add_on therapy to mirtazapine in the treatment of major depressive disorder in terminally ill cancer patients: A four_week,randomized, double_blinded, placebo_controlled study. *Eur Neuropsychopharmacol*; 24(4):491–8. doi: 10.1016/j.euroneuro.
 133. Novianti P.W., Roes K.C.B., van der Tweel I. (2014). Estimation of between_trial variance in sequential meta_analyses: a simulation study. *Contemp Clin Trials*. 2014 Jan;37(1):129–38. doi: 10.1016/j.cct.2013.11.012.
 134. Uddin MJ, Groenwold RH, de Boer A, Belitser SV, Roes KCB, Hoes AW, Klungel OH. (2014). Performance of instrumental variable methods in cohort and nested case_control studies: a simulation study. *Pharmacoepidemiol Drug Saf*. 2014 Feb;23(2):165–77. doi: 10.1002/pds.3555.
 135. Tanniou J. van der Tweel I., Teerenstra S., Roes K.C.B. (2014). Level of evidence for promising subgroup findings in an overall non_significant trial. *Trials* 11/2013; 14(Suppl 1):O105. DOI:10.1186/1745_6215_14_S1_O105.
 136. Walenkamp MM, Roes K.C.B., Bhandari M, Goslings JC, Schep NW (2013). Multiple testing in orthopedic literature: a common problem? *BMC Res Notes*. 2013 Sep 21;6:374.
 137. Nikolakopoulos S., van der Wal W.M., Roes K.C.B. (2013). Bayesian_frequentist decision_making in clinical development and predictive value of biomarkers. *Journal of Biopharmaceutical Statistics*.
 138. Sabrina Siregar, MD1, Kit C.B. Roes, PhD2, A.H.M. van Straten, MD PhD3, Michiel L. Bots, MD PhD2, Yolanda van der Graaf, MD PhD2, Lex A. van Herwerden, MD PhD1, Rolf H.H. Groenwold, MD PhD2 (2013). Statistical methods to monitor risk factors in a clinical database: the example of a national cardiac surgery registry Circ Cardiovascular Quality and outcomes. 2013. Jan 1; 6(1):110–8.
 139. Roes K.C.B. Discussion to: Group sequential tests for delayed responses, by Lisa V. Hampson, Christopher Jennison J. R. *Statist. Soc. B* (2013) 75, Part 1, pp. 1–37
 140. Verkooijen HM, Roes K, van Gils CH. Cohort multiple randomised controlled trial design: Een oplossing voor de evaluatie van meerdere interventies? *Ned Tijdschr Geneesk*. 2013;157:A5762 Tweel I van der, Roes KCB. Wanneer is er genoeg 'bewijs'? Methoden voor tussentijdse analyses van klinisch onderzoek. *Ned Tijdschr Geneesk*. 2013;157:A5660
 141. Bjorkman S.T., Ireland Z., Fan X, van der Wal W., Roes K.C.B., Colditz P., Cacha Peeters_Scholte C. (....). Short_term dose_response of 2_iminobiotin immediately post insult in the neonatal piglet following hypoxia_ischemia. *Stroke*.
 142. Boessen R, Groenwold RH, Knol MJ, Grobbee DE, Roes KC. Comparing HAMD(17) and HAMD subscales on their ability to differentiate active treatment from placebo in randomized controlled trials. *J Affect Disord*. 2012 Sep 6. [Epub ahead of print] PubMed PMID: 22959683.
 143. Wangge G, Roes KC, de Boer A, Hoes AW, Knol MJ. The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants. *CMAJ*. 2012 Aug 20. [Epub ahead of print] PubMed PMID: 22908144.
 144. van der Graaf R, Roes KC, van Delden JJ. Adaptive trials in clinical research: scientific and ethical issues to consider. *JAMA*. 2012 Jun 13;307(22):2379–80. PubMed PMID: 22692169.
 145. Boessen R, Groenwold RH, Knol MJ, Grobbee DE, Roes KC. Classifying responders and non_responders; does it help when there is evidence of differentially responding patient groups? *J Psychiatr Res*. 2012 Sep;46(9):1169–73. Epub 2012 Jun PubMed PMID: 22658815.
 146. Frederieke van der Baan; Olaf H Klungel; Antoine C.G. Egberts; Hubert G.M. Leufkens; Diederick E. Grobbee; Kit C.B. Roes; Mirjam J Knol (2011). Pharmacogenetics in Randomized Controlled Trials: considerations for trial design. *PLoS ONE*.
 147. Groenwold RH, Donders AR, Roes KC, Harrell FE Jr, Moons KG. Dealing with missing outcome data in randomized trials and observational studies. *Am J Epidemiol*. 2012 Feb 1;175(3):210–7. Epub 2011 Dec 23. PubMed PMID: 22262640.
 148. Boessen R, Knol MJ, Groenwold RH, Grobbee DE, Roes KC. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: Application to antidepressant trials. *Clin Trials*. 2012;9(5):578–87. doi: 10.1177/1740774512456454. PubMed PMID: 23060319.
 149. Boessen R., M.J. Knol M.J., R.H. Groenwold, K.C.B. Roes. Validation and Predictive Performance Assessment of Clinical Trial Simulation Models. *Clin. Pharm & Ther.* Advance online publication 16 February 2011. doi: 10.1038/clpt.2010.277
 150. van Eijk M. J. , K.C.B. Roes, M.L.H Honing, M.A. Kuiper, A. Karakus, M. van der Jagt, P.E. Spronk, W.A. van Gool, R.C. van der Mast, J. Kesecioglu, A.J.C. Slooter (2010). Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double_blind, placebo_controlled randomised trial. *Lancet*, November 5, DOI:10.1016/S0140_6736(10)61855_7
 151. Wangge G, Klungel OH, Roes KCB, de Boer A, Hoes AW, Knol M.J. (2010) Room for Improvement in Conducting and Reporting Non_Inferiority Randomized Controlled Trials on Drugs: A Systematic Review. *PLoS ONE* 5(10): e13550. doi:10.1371/journal.pone.0013550
 152. Wangge G., O H Klungel O.H., Roes, K.C.B., de Boer A., Hoes A.W., Knol M.J. (2010) Interpretation and Inference in Noninferiority Randomized Controlled Trials in Drug Research. *Clinical Pharmacology & Therapeutics*, 88 3, 420–423.
 153. Williams Z., Roes K.C.B., Howitt N. (2009). Qualified Statisticians in the European Pharma Industry: Present and Future Directions. *DIA Journal*, 43, p. 573–583.
 154. Roes K.C.B. (2004). Dynamic allocation as balancing act. *Pharmaceutical Statistics*, 3, p. 187–191. Mast de J., Roes K.C.B. (2004). Robust Individuals Control Chart for Exploratory Analysis. *Quality Engineering*, 16(3), p. 407–421.
 155. Mast de J., Roes K.C.B., Does R.J.M.M. (2001). The multi_vari chart – A systematic approach. *Quality Engineering*, 13(3), p. 437–447.
 156. Radhakishun F.S., van den Bos J., van der Heijden B.C.J.M., Roes K.C.B., O'Hanlon J.F. (2000). Mirtazapine effects on alertness and sleep in patients as recorded by interactive telecommunication during treatment with different dose regimens. *Journal of Clinical Psychopharmacology*, 20, p. 531–537.

157. Does R.J.M.M., Roes K.C.B., Trip A. (1999). Statistical Process Control in industry. Kluwer Academic Publishers.
158. Does R.J.M.M., Roes K.C.B., Trip A. (1999). Handling multivariate problems with univariate control charts. Journal of Chemometrics, 13, p. 353_369.
159. Roes K.C.B., Does R.J.M.M., Jonkers B. (1999). Effective application of Q(R) charts in low volume manufacturing. Quality and Reliability Engineering International, 15, p. 175_190.
160. Boon P.C., Roes K.C.B. (1999). Design and analysis issues for crossover designs in Phase I clinical studies. Journal of Biopharmaceutical statistics, 9, p. 109_128.

Projects

Current involvement as Work Package and/or Tasks lead:

Horizon Europe: (1) MORE-Europa: More Effectively Using Registries to Support Patient Centered Regulatory and Health Technology Assessment decision making. (2) SIMPATHIC: Innovative approach to identify and develop targeted (re-purposed) drugs for rare diseases with shared pathophysiological mechanisms. (3) INVENTS: Innovative designs, extrapolation, simulation methods and evidence tools for rare diseases addressing regulatory needs.

IHI funded: Realised: Developing operational and methodological tools and resources that can dramatically advance the clinical evaluation of new treatments for rare and ultra rare diseases.

Current involvement in advisory role: (1) ERDERA. (2) EU TRICALS Consortium for clinical trials in Amyotrophic Lateral Sclerosis.

Past project: Principal Investigator of EU FP 7 project on Methodology for clinical trials in small populations (Asterix project; completed 2017).

Memberships

Chair EMA Methodology Working Party.

Member of clinical research grant proposal review boards for ZonMW (Netherlands) and KCE (Belgium).

Member Regulatory Science Network Netherlands.

Member IRDiRC Taskforce on Methodology for Clinical Trials in Rare diseases.

Member/chair of multiple independent Data Monitoring Committees, including for Corcept Therapeutics (ALS, until March 2025) and F. Hoffman-La Roche (Huntington's disease, current).

Other Relevant Information